Compare Hewlett Packard Enterprise Co (HPE) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hewlett Packard Enterprise Co vs Merck & Co., Inc. — how do they compare? Hewlett Packard Enterprise Co trades at $46.82 (market cap $59.01B), while Merck & Co., Inc. trades at $125.31 (market cap $307.25B). The key difference: Merck & Co., Inc. is far larger — about 5.2× Hewlett Packard Enterprise Co's market cap, and Merck & Co., Inc. pays the higher dividend (2.73%). Which is the better fit depends on your goals.
| HPE | MRK | |
|---|---|---|
Market Cap | $59.01B | $307.25B |
Sector | Technology | Health |
52-Week High | $56.14 | $129.52 |
52-Week Low | $19.81 | $77.60 |
Enterprise Value | $74.96B | $350.66B |
Dividend Yield | 1.28% | 2.73% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HPE trades at $44.95, down 1.9% today, with a bearish technical signal despite recent earnings beats. The stock shows strong AI infrastructure momentum with a record $6.3 billion backlog, though 2025 net income declined sharply to $57 million. Valuation metrics include a P/E of 42.8 and P/S of 1.6, while analyst consensus favors a Buy rating with a $69.69 price target representing 55% upside potential.
HPE's transformation into an AI infrastructure leader presents significant growth opportunity, supported by strong enterprise demand and improving cash flow projections. Key risks include competitive pressure in AI hardware, execution challenges with Juniper integration, and volatile cash flow patterns. The current valuation appears reasonable given AI growth prospects despite near-term profitability concerns.
Merck (MRK) trades at $125.25, down 1.76% on the day, with a neutral technical signal. The company reported strong earnings beats in recent quarters, with Q1 2026 results surpassing expectations. Fundamentals show robust profitability with a 73.91% gross margin and 13.59% net margin, though valuations are elevated with a P/E of 35.04. Recent news highlights the company's strategic acquisition of Terns Pharmaceuticals to bolster its oncology pipeline.
The outlook is supported by a strong analyst consensus with a $137.30 price target and 68% buy ratings, but risks include high valuation multiples, competitive pressures in oncology, and significant capital expenditure for pipeline development as indicated by negative investing cash flow trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hewlett Packard Enterprise Co
Hewlett Packard Enterprise is an information technology vendor that provides hardware and software to enterprises. Its primary product lines are compute servers, storage arrays, and networking equipment.
Read more on HPE →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
